Healthcare Tech Outlook: Specials Magazine

Price transparency has become one of the most scrutinized and operationally challenging mandates facing U.S. hospitals—particularly Critical Access Hospitals (CAHs), which must meet the same federal requirements as large health systems with only a fraction of the staff and resources. As enforcement intensifies and regulatory expectations expand, the gap between compliance in theory and execution in practice has become increasingly visible. After an extensive review process that included interviews with CAH executives, revenue cycle leaders, and healthcare revenue cycle management (RCM) vendors—many of whom do not offer price transparency solutions—Healthcare Tech Outlook has selected Hospital Pricing Specialists (HPS) as its 2026 Best Price Transparency Vendor for Critical Access Hospitals. This designation reflects not marketing claims, but observed performance: repeatable compliance outcomes, defensible methodologies, and a depth of pricing expertise that CAH leaders consistently cited as differentiating in an increasingly crowded vendor landscape. An Independent Evaluation Grounded in Market Feedback Healthcare Tech Outlook’s evaluation focused on a central question voiced repeatedly by rural hospital leaders: Which vendors actually understand how Critical Access Hospitals operate financially—and can translate federal price transparency rules into something workable and defensible? Interviews with CAH CFOs and revenue cycle executives revealed a common theme. Many price transparency tools currently on the market were designed for large, urban health systems and later “scaled down” for rural use. This approach often leaves CAHs with tools that technically meet minimum publishing requirements but fail under audit, payer scrutiny, or patient use.

Across biotech and pharmaceutical development, the central constraint is time. When studies miss enrollment targets—whether in early programs or trials that slip into rescue—timelines extend, costs rise, investment risk increases, and time to market is pushed further out. These overruns do not stay contained within a single trial but create a ripple effect, adding strain to already limited site capacity. TrialWire was built to address this execution risk directly by accelerating enrollment in a way that sites can sustain. Its AI-powered clinical trial patient recruitment platform helps sponsors and CROs move from study approval to active patient screening within 24 hours. Rather than driving volume into sites, the platform is designed to advance only highly AI-screened and qualified participants who are ready for site evaluation. “Speed only matters if it holds up under real site conditions,” says Susan Fitzpatrick-Napier, CEO. “If recruitment creates more work for coordinators or sends patients without sufficient context or timelines, then timelines don’t improve. We focus on building speed that sites can sustain.” Faster Enrollment with Better-fit Patients Traditional database-based recruitment relies on static lists that are often outdated by the time a study launches, sending patients who are no longer eligible or have no current intent into the funnel. TrialWire moves away from database-driven recruitment entirely, identifying potential participants in real time based on active health-related online intent and expressed TA (therapeutic area). Engaging people when they are actively searching online for health information attracts individuals who are already motivated to explore solutions, creating a stronger starting point for screening and site engagement..